Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global biomarkers market size reached US$ 68.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 139.8 Billion by 2028, exhibiting a growth rate (CAGR) of 11.5% during 2023-2028.
Biomarkers, also known as biological markers, are molecules or genes that are used as indicators of the health or status of an organ, tissue, or cell. In addition to blood and bodily fluids, biomarkers are also found in tissues. In the discovery and development of new drugs, biomarkers are used for risk assessment, molecular diagnostics, disease diagnosis, DNA fingerprinting, and eliminating complexity. As a result, they play a crucial role in improving the drug development process, drug validation and testing, sample preparation and assay development. Biomarkers are often integrated with key imaging technologies that can provide clear images of oncology tumors and other problems while also eliminating the possibility of radiation exposure during CT scans and MRI scans.
Biomarkers Market Trends:
The market is majorly driven by the rising incidences of numerous chronic diseases among the masses, particularly in the geriatric population. In addition to this, the increasing implementation of biomarkers in infectious disease diagnosis is propelling the market. Moreover, continual developments in biomarker-based diagnostics, such as biomarker signatures resulting in faster drug development, non-invasive testing, and early diagnosis, are also creating a positive market outlook. In line with this, the rapid utilization of biomarkers in the development of companion diagnostics to identify drug target molecules is providing an impetus to the market. Also, the escalating demand for personalized medicine, along with a paradigm shift toward biomarker studies from conventional pathophysiology and epidemiology methods, is fueling the market. Furthermore, a considerable rise in the number of contract research organizations facilitating cost-efficient clinical trials are creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities and the increasing medical expenditure.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarkers market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, type, disease, application and end user.
Breakup by Product:
Consumables
Services
Software
Breakup by Type:
Efficacy Biomarkers
Safety Biomarkers
Validation Biomarkers
Breakup by Disease:
Cancer
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Renal Disorders
Others
Breakup by Application:
Diagnostics
Drug Discovery and Development
Personalized Medicine
Others
Breakup by End User:
Pharmaceutical and Biotechnology Companies
Diagnostic and Research Laboratories
Hospitals and Specialty Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
1. What was the size of the global biomarkers market in 2022?
2. What is the expected growth rate of the global biomarkers market during 2023-2028?
3. What are the key factors driving the global biomarkers market?
4. What has been the impact of COVID-19 on the global biomarkers market?
5. What is the breakup of the global biomarkers market based on the product?
6. What is the breakup of the global biomarkers market based on the type?
7. What is the breakup of the global biomarkers market based on disease?
8. What is the breakup of the global biomarkers market based on the application?
9. What is the breakup of the global biomarkers market based on the end user?
10. What are the key regions in the global biomarkers market?
11. Who are the key players/companies in the global biomarkers market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Biomarkers Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Product
- 6.1 Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Services
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Software
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 7 Market Breakup by Type
- 7.1 Efficacy Biomarkers
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Safety Biomarkers
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Validation Biomarkers
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 8 Market Breakup by Disease
- 8.1 Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cardiovascular Disorders
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Neurological Disorders
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Immunological Disorders
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Renal Disorders
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 9 Market Breakup by Application
- 9.1 Diagnostics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Drug Discovery and Development
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Personalized Medicine
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 10 Market Breakup by End User
- 10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Diagnostic and Research Laboratories
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Hospitals and Specialty Clinics
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
- 11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Asia-Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
- 12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
- 13 Value Chain Analysis
- 14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
- 15 Price Analysis
- 16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Agilent Technologies Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Bio-Rad Laboratories Inc.
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
- 16.3.2.4 SWOT Analysis
- 16.3.3 Charles River Laboratories International Inc.
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.3.4 SWOT Analysis
- 16.3.4 Epigenomics AG
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.4.4 SWOT Analysis
- 16.3.5 Eurofins Scientific SE
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.5.4 SWOT Analysis
- 16.3.6 Merck KGaA
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
- 16.3.7 Perkinelmer Inc.
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.8 Qiagen N.V
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.8.3 Financials
- 16.3.8.4 SWOT Analysis
- 16.3.9 Quanterix Corporation
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.10 SphingoTec GmbH
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.11 Thermo Fisher Scientific Inc.
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.11.4 SWOT Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook